PriceTargets.com logo

PureTech Health - PRTC Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $45.00
  • Forecasted Upside: 107.42%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$21.70 As of 11/20/2024 01:00 AM ET
▲ +0.44 (2.07%)

This chart shows the closing price for PRTC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PureTech Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTC

Analyst Price Target is $45.00
▲ +107.42% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for PureTech Health in the last 3 months. The average price target is $45.00, with a high forecast of $45.00 and a low forecast of $45.00. The average price target represents a 107.42% upside from the last price of $21.70.

This chart shows the closing price for PRTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 2 polled investment analysts is to buy (strong buy) stock in PureTech Health. This rating has held steady since July 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/9/2024Leerink PartnrsUpgradeStrong-Buy
9/9/2024Leerink PartnersInitiated CoverageOutperform$58.00 ➝ $45.00
8/25/2022Piper SandlerBoost TargetOverweight$37.00 ➝ $44.00
6/20/2022Piper SandlerSet Target$37.00
6/15/2022Leerink PartnersLower TargetOutperform$70.00 ➝ $66.00
6/14/2022Piper SandlerLower Target$72.00 ➝ $37.00
1/7/2022Leerink PartnersLower TargetOutperform$76.00 ➝ $70.00
8/25/2021Leerink PartnersBoost TargetOutperform$74.00 ➝ $76.00
8/25/2021Piper SandlerLower TargetOverweight$76.00 ➝ $72.00
2/10/2021Piper SandlerBoost Target$66.00 ➝ $76.00
1/15/2021Leerink PartnersInitiated CoverageOutperform$70.00
11/17/2020Piper SandlerInitiated CoverageOverweight
(Data available from 11/21/2019 forward)

News Sentiment Rating

1.42 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

PureTech Health logo
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $21.70
Low: $21.45
High: $21.70

50 Day Range

MA: $20.50
Low: $19.29
High: $22.84

52 Week Range

Now: $21.70
Low: $17.08
High: $34.00

Volume

2,048 shs

Average Volume

4,169 shs

Market Capitalization

$519.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of PureTech Health?

The following Wall Street sell-side analysts have issued reports on PureTech Health in the last year: Leerink Partners, and Leerink Partnrs.
View the latest analyst ratings for PRTC.

What is the current price target for PureTech Health?

0 Wall Street analysts have set twelve-month price targets for PureTech Health in the last year. Their average twelve-month price target is $45.00, suggesting a possible upside of 107.4%. Leerink Partners has the highest price target set, predicting PRTC will reach $45.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $45.00 for PureTech Health in the next year.
View the latest price targets for PRTC.

What is the current consensus analyst rating for PureTech Health?

PureTech Health currently has 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for PRTC.

What other companies compete with PureTech Health?

Other companies that are similar to PureTech Health include Apogee Therapeutics, Centessa Pharmaceuticals, Evotec, Harmony Biosciences and Disc Medicine. Learn More about companies similar to PureTech Health.

How do I contact PureTech Health's investor relations team?

PureTech Health's physical mailing address is 6 TIDE STREET SUITE 400, BOSTON MA, 02210. The company's listed phone number is 617-482-2333 and its investor relations email address is [email protected]. The official website for PureTech Health is www.puretechhealth.com. Learn More about contacing PureTech Health investor relations.